Biomedical applications of gold and gold compounds

Gold: Science and Applications

Volumn , Issue , 2009, Pages 217-230

  Pacheco, Elizabeth A ^a   Tiekink, Edward R T ^b   Whitehouse, Michael W ^c  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871645479     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (63)

1. Clinical pharmacology of gold, W. F. Kean and I. R. L. Kean, Inflammopharmacology, 2008, 16, 107.
2. Evaluation of chemical constituents and free-radical scavenging activity of Swarna bhasma (gold ash), an ayurvedic drug, A. Mitra, S. Chakraborty, B. Auddy, et al., J. Ethnopharm., 2002, 80, 147.
3. Gold compounds in medicine: potential anti-tumour agents, E. R. T. Tiekink, Gold Bull., 2003, 36, 117.
4. Crystal structure of the antiarthritic drug gold thiomalate (myochrysine): A double-helical geometry in the solid state, R. Bau, J. Am. Chem. Soc., 1998, 120, 9380.
5. 2O, H. Ruben, A. Zalkin, M. O. Faltens, and D. H. Templeton, Inorg. Chem., 1974, 13, 1836.
6. 9PS, D. T. Hill and B. M. Sutton, Cryst. Struct. Comm., 1980, 9, 679.
7. Difference in the pharmacokinetics, protein binding, and cellular distribution of gold when different gold compounds are used, J. D. Herrlinger, Modern Aspects of Gold Therapy, eds. M. Schettenkirchner and W. Muller, 1983, 52-57, Karger, Basel.
8. Determination of thiomalate in physiological fluids using high performance liquid chromatography and electrochemical detection, S. R. Rudge, D. Perret, P. L. Drury, et al., J. Pharm. Bio. Anal., 1983, 1, 205.
9. A biological effect on platelets by the minor component of gold sodium thiomalate - a by-product of heat sterilization and exposure to light, W. F. Kean, C. J. Lock, Y. B. Kassam, et al., Clin. Exp. Rheum., 1984, 2, 321.
10. The mammalian biochemistry of gold: An inorganic perspective of chrysotherapy, C. F. Shaw, Inorg. Perspec. Biol. Med., 1979, 2, 287.
11. Bis(L-cysteinato)gold(I): chemical characterization and identification in renal cortical cytoplasm, C. F. Shaw, G. Schmitz, H. O. Thompson, et al., J. Inorg. Biochem., 1979, 10, 317.
12. Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long term oral gold, E. H. Giannini, E. J. Brewer, and D. A. Person, Ann. Rheum. Dis., 1984, 43, 228.
13. Biologic actions and pharmacokinetic studies of auranofin, D. T. Walz, M. J. DiMartino, D. E. Griswold, et al., Am. J. Med., 1983, 75, 90.
14. Auranofin versus injectable gold. Comparison of pharmacokinetic properties, A. K. Blocka, Am. J. Med., 1983, 75, 114.
15. 195Au-labeled aurothiomalate in blood, N. L. Gottlieb, P. M. Smith, and E. M. Smith, Arthritis Rheum., 1974, 17, 171.
16. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis, J. R. Ward, N. J. Williams, M. J. Egger, et al., Arthritis Rheum., 1983, 26, 1303.
17. Pharmacokinetics of auranofin in animals, A. P. Intoccia, T. L. Glanagan, D. T. Walz, et al., Bioinorganic Chemistry of Gold Coordination Compounds, eds. B. M. Sutton, and R. G. Franz, 1983, 21-33, SK&F, Philadelphia.
18. Aurocyanide, dicyano-aurate(I), a pharmacologically active metabolite of medicinal gold complexes, G. G. Graham, M. W. Whitehouse, and G. R. Bushell, Inflammopharmacology, 2008, 16, 126.
19. 2] in the formation of gold metabolites, C. F. Shaw III, S. Schraa, E. Gleichmann, et al., Metal-Based Drugs, 1994, 1, 351.
20. Gold-based therapeutic agents, C. F. Shaw, Chem. Rev., 1999, 99, 2589.
21. Uber bacteriologische Forschung, R. Koch, Dtsch. med. Wochenschr., 1890, 16, 756.
22. Dicyanogold(I) is a common human metabolite of different gold drugs, R. C. Elder, Z. Zhao, Y. Zhang, et al., J. Rheumatol., 1993, 20, 268.
23. Chrysotherapy: A synoptic review, R. Eisler, Inflammation Res., 2003, 52, 487.
24. The activation of gold complexes by cyanide produced by polymorphonuclear leukocytes. II. Evidence for the formation and biological activity of aurocyanide, G. G. Graham and M. M. Dale, Biochem. Pharmacol., 1990, 39, 1697.
25. Gold(III)-induced oxidation of glycine, Z. Juan, G. Zijian, J. A. Parkinson, et al. Chem. Commun., 1999, 15, 1347.
26. Gold coordination complexes as anticancer agents, I. Kostova, Anti-Cancer Agents Med. Chem., 2006, 6, 19.
27. Management of rheumatoid arthritis: rationale for the use of colloidal metallic gold, G. E. Abraham, and P. B. Himmel, J. Nutrit. Environ. Med., 1997, 7, 295.
28. Nanogold-pharmaceutics: (i) The use of colloidal gold to treat experimentally-induced arthritis in rat models; (ii) Characterization of the gold in Swarna bhasma a microparticulate use in traditional Indian medicine, C. L. Brown, G. Bushell, M. W. Whitehouse, et al., Gold Bulletin, 2007, 40, 245.
29. Platinum binding to DNA: Structural controls and consequences, T. W. Hambley, J. Chem. Soc., 2001, 2711.
30. Anti-cancer potential of gold complexes, E. R. T. Tiekink, Inflammopharmacology, 2008, 16, 138.
31. Cancer in rheumatoid arthritis: a prospective long-term study of mortality, J. F. Fries, D. Block, P. Spitz, and D. M. Mitchell, Am. J.Med., 1985, 78, 56.
32. Treatment of rheumatoid arthritis with cytostatic drugs, I. Lorenzen, Ann. Clin. Res., 1975, 7, 195.
33. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis, J. R. Ward, Am. J. Med., 1988, 85, 39.
34. Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes, C. K. Mirabelli, R. K. Johnson, D. T. Hill, et al., J. Med. Chem., 1986, 29, 218.
35. Gold derivatives for the treatment of cancer, E. R. T. Tiekink, Crit. Rev. Oncol. Hematol., 2002, 42, 225.
36. Gold compounds and their application in medicine, E. A. Pacheco, E. R. T. Tiekink, and M. W. Whitehouse, in Gold Chemistry. Applications and Future Directions in Life Sciences, 2009, 283-319. ed. F. Mohr, John Wiley & Sons, in press.
37. Anti-tumor activity, in vitro and in vivo, of some triphenylphosphinegold(I) thionucleobases, L. K. Webster, S. Rainone, E. Horn, and E. R. T. Tiekink, Metal-Based Drugs, 1996, 3, 63.
38. In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane] gold(I) chloride, S. J. Berners-Price, C. K. Mirabelli, R. K. Johnson, et al., Cancer Res., 1986. 46, 5486.
39. Role of lipophilicity in determining the cellular uptake and antitumor activity of gold phosphine complexes, M. J. McKeage, S. J. Berners-Price, P. Galletis, et al., Cancer Chemother. Pharmacol., 2000, 46, 343.
40. Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: The possible role of mitochondria, M. J. McKeage, L. Maharaj, and S. J. Berners-Price, Coord. Chem. Rev., 2002, 232, 127.
41. Targeting the mitochondrial cell death pathway with gold compounds, P. J. Barnard and S. J. Berners-Price, Coord. Chem. Rev., 2007, 251, 1889.
42. A screening strategy for metal antitumor agents as exemplified by gold(III) complexes, S. P. Fricker, Metal Based Drugs, 1999, 6, 291.
43. Antitumor properties of some 2-(dimethylamino)methyl.phenylgold(III) complexes, R. G. Buckley, A. M. Elsome, S. P. Fricker, et al., J. Med. Chem., 1996, 39, 5208.
44. Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds, L. Messori, F. Abbate, G. Marcon, et al., J. Med. Chem., 2000, 43, 3541.
45. Cytotoxicity profiles for a series of triorganophosphinegold(I) dithiocarbamates and triorganophosphinegold(I) xanthates, D. de Vos, S. Y. Ho, and E. R. T. Tiekink, Bioinorg. Chem. Appl., 2004, 2 141.
46. A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts, V. Milacic, D. Chen, L. Ronconi, et al., Cancer Res., 2006, 66, 10478.
47. Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties, L. Ronconi, C. Marzano, P. Zanello, et al., J. Med. Chem., 2006, 49, 1648.
48. Gold dithiocarbamate derivatives as potential antineoplastic agents: Design, spectroscopic properties, and in vitro antitumor activity, L. Ronconi, L. Giovagnini, C. Marzano, et al., Inorg. Chem., 2005, 44, 1867.
49. Review of gold(I) N-heterocyclic carbenes, I. J. B. Lin and C. S. Vasam, Can. J. Chem., 2005, 83, 812.
50. Mitochondrial permeability transition induced by dinuclear gold(I)-carbene complexes: Potential new antimitochondrial antitumor agents, P. J. Barnard, M. V. Bakers, S. J. Berners-Price, and D. A. Day, J. Inorg. Biochem., 2004, 98, 1642.
51. Synthesis and structural characterization of linear Au(I) N-heterocyclic carbene complexes: New analogs of the Au(I) phosphine drug Auranofin, M. V. Baker, P. J. Barnard, S. J. Berners-Price, et al., J. Organomet. Chem., 2005, 690, 5625.
52. Gold nanoparticles: assembly, supramolecular chemistry, quantum-size-related properties, and applications toward biology, catalysis, and nanotechnology, M-C. Daniel and D. Astruc, Chem. Rev., 2005, 104, 293.
53. Therapeutic possibilities of plasmonically heated gold nanoparticles, D. Pissuwan, S. M. Valenzuela, and M. B. Cortie, Trends Biotech., 2006, 24, 62.
54. Factors determining the efficacy of nuclear delivery of antisense oligonucleotides by gold nanoparticles, Y. Liu and S. Franzen, Bioconjugate Chem., 2008, 19, 1009.
55. Colloidal metallic gold is not bio-inert, C. L Brown, M. W. Whitehouse, E. R. T. Tiekink, and G. R. Bushell, Inflammopharmacology, 2008, 16, 133.
56. 2, R. A. Sanchez-Delgado, K. Lazardi, L. Rincon, et al., J. Med. Chem., 1993, 36, 2041.
57. Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes, M. Navarro, F. Vasquez, R. A. Sanchez-Delgado, et al. J. Med. Chem., 2004, 47, 5204.
58. Organic thio compounds having a sulfur-gold linkage as specific inhibitors for retrovirus reverse transcriptase, and their application as medicaments, H. Blough, Abstracts 3rd International Conf. Gold and Silver in Medicine, 1993, 14, Manchester, UK.
59. Aurothiolates inhibit HIV-1 infectivity by gold(I) ligand exchange with a component of the virion surface, T. Okada, B. K. Patterson, S. Q. Ye, and M. W. Gurney, Virology, 1993, 192, 631.
60. Transport of the dicyanogold(I) anion, K. Tepperman, Y. Zhang, P. W. Roy, et al., Metal-Based Drugs, 1994, 1, 433.
61. Inhibition of HIV fusion with multivalent gold nanoparticles, M-C. Bowman, T. E. Ballard, C. J. Ackerson, et al., J. Am. Chem. Soc., 2008, 130, 6896.
62. Alternative agents in asthma, A. J. Frew and M. J. Plummeridge, J. Allergy Clin. Immunol., 2001, 108, 3.
63. A placebo controlled multicenter study of auranofin in the treatment of corticosteroid-dependent chronic severe asthma, I. L. Bernstein, D. I. Bernstein, J. W. Dubb, et al., J. Allergy Clin. Immunol., 1996, 98, 317.